Skip to content
Taxonomy
CMT2S Breakthrough
In a recent announcement, Vanda Pharmaceuticals Inc. shared that the Read More
CMTA Alliance Partner, Applied Therapeutics, Announces Positive 12-Month Results in its Ongoing INSPIRE Phase III Trial for CMT-SORD
In a statement released on February 15, 2024, by Charcot-Marie-Tooth Read More
The CMTA Appoints Professor Charlotte Sumner, M.D., to its Scientific Advisory Board
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
CMTA Appoints Biotech Industry Veteran Suzanne Bruhn, PhD as New CEO
GLENOLDEN, Pa., November 6, 2023 – The Charcot-Marie-Tooth Association announced Read More
CMTA Funds Preclinical Work on Modulating Unfolded Protein Response in CMT1B Mice
The Charcot-Marie-Tooth (CMT) Association announced a $33,000 grant on April Read More
Vera Fridman, MD joins the CMTA STAR Advisory Board
In a suite of exciting appointments, the Charcot-Marie-Tooth Association (CMTA) Read More
Bruce R Conklin, MD Joins the CMTA STAR Advisory Board
In a suite of exciting appointments, the Charcot-Marie-Tooth Association (CMTA) Read More
Diana Bharucha-Goebel, MD Joins the CMTA-STAR Advisory Board
In a suite of exciting appointments, the Charcot-Marie-Tooth Association (CMTA) Read More
Data Shows Benefit with PXT3003 in Patients with CMT1A
New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit Read More
Orphan Drug Designation for TSHA-120 for Treatment of GAN
Taysha Gene Therapies Receives Orphan Drug Designation from the European Read More
